Evidence map›Paper›PMID 42481757›Full record

ArticleNature genetics2026

SUMOylation enhances DNMT1 function to repress mega-intergenic RNAs and viral mimicry.

Brian J Liddicoat, Jesse J Balic, Wendy Jia, Andrea Gillespie, Andrew B Das, Laura Scolamiero, Naiara G Bediaga, Yih-Chih Chan, Christa van der Maarel, Andrew A Guirguis and 21 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Brian J Liddicoat *Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Jesse J Balic *Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. jesse.balic@petermac.org.ORCID http://orcid.org/0000-0002-9681-6834
Wendy JiaPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Andrea GillespiePeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Andrew B DasPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Laura ScolamieroPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Naiara G BediagaPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-7363-0068
Yih-Chih ChanPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-2177-5406
Christa van der MaarelPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Andrew A GuirguisPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-3134-0596
Kelsy PrestPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Oliver J SinclairPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Laure TalarmainPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Cassandra LitchfieldPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-9374-1681
Enid Y N LamPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-5843-7836
Sebastian HollizeckPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-9504-3497
John R HortonDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9749-8068
Benjamin KroegerDepartment of Anatomy and Developmental Biology, and Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-1479-3841
Tao WangMedicinal Science and Technology, GlaxoSmithKline, Collegeville, PA, USA.
Francesca ZappacostaMedicinal Science and Technology, GlaxoSmithKline, Collegeville, PA, USA.
Roland S AnnanMedicinal Science and Technology, GlaxoSmithKline, Collegeville, PA, USA.
Rab K PrinjhaGlaxoSmithKline R&D Stevenage, Stevenage, UK.ORCID http://orcid.org/0000-0002-2666-3326
Melissa B PappalardiCancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA.ORCID http://orcid.org/0000-0001-8457-1625
Michael T McCabeCancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA.
Ching-Seng AngBio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Victoria, Australia.
Matthew S GrausThe David Richmond Laboratory for Cardiovascular Development: Gene Regulation and Editing, The Centenary Institute, The University of Sydney, Camperdown, New South Wales, Australia.ORCID http://orcid.org/0000-0001-5470-4837
Mathias FrancoisThe David Richmond Laboratory for Cardiovascular Development: Gene Regulation and Editing, The Centenary Institute, The University of Sydney, Camperdown, New South Wales, Australia.
Kieran F HarveyPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-7845-369X
Sarah-Jane DawsonPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-8276-0374
Xiaodong ChengDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6967-6362
Mark A DawsonPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia. mark.dawson@petermac.org.ORCID http://orcid.org/0000-0002-5464-5029

Funding

Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and MechanismsR35GM134744 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Xiaodong Cheng · 2020 to 2026
$4.5M
Department of Health | National Health and Medical Research Council (NHMRC) 1128984Department of Health | National Health and Medical Research Council (NHMRC) 1196749Department of Health | National Health and Medical Research Council (NHMRC) 1196755Department of Health | National Health and Medical Research Council (NHMRC) 2003909Howard Hughes Medical Institute (HHMI) 55008729NIGMS NIH HHS R35 GM134744U.S. Department of Health & Human Services | National Institutes of Health (NIH) R35GM134744
6 · The paper itself

Abstract

DNA methyltransferase 1 (DNMT1) is essential for mammalian development and is frequently dysregulated in cancer. While its recruitment to hemimethylated DNA by UHRF1 is well established, its broader chromatin occupancy and regulation remain unclear. We show that DNMT1 is enriched at unmethylated CpG islands of actively transcribed genes largely by its CXXC domain. Upon selective catalytic inhibition, DNMT1 redistributes to partially methylated, inaccessible regions in a UHRF1-dependent and RFTS-dependent manner. Although coding gene expression is largely unchanged, sustained DNMT1 inhibition and subsequent global DNA hypomethylation trigger reactivation of endogenous viral elements, including an uncharacterized class of double-stranded RNA mega-intergenic transcripts (mintRNAs) driving a cell-intrinsic viral mimicry response. We identify RNF4 as a major regulator of DNMT1 catalytic function that, beyond its canonical role in DNA-protein crosslink resolution, controls the levels of SUMOylated DNMT1, establishing SUMOylation as a rheostat that regulates DNMT1 activity to maintain DNA methylation and safeguard against viral mimicry.

Indexed as

DNA (Cytosine-5-)-Methyltransferase 1Molecular MimicrySumoylationAnimalsCCAAT-Enhancer-Binding ProteinsCpG IslandsDNA MethylationHumansNuclear ProteinsTranscription FactorsUbiquitin-Protein LigasesCCAAT-Enhancer-Binding ProteinsDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanNuclear ProteinsTranscription FactorsUbiquitin-Protein LigasesUHRF1 protein, human

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.